HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea · Delayed Price · Currency is KRW 12,340
-660 (-5.08%)
May 21, 2026, 3:30 PM KST
HLB Pharmaceutical Revenue
In the year 2025, HLB Pharmaceutical had annual revenue of 205.58B KRW with 49.97% growth. HLB Pharmaceutical had revenue of 63.42B in the quarter ending December 31, 2025, with 91.67% growth.
Revenue
205.58B
Revenue Growth
+469.48%
P/S Ratio
0.89
Revenue / Employee
n/a
Employees
n/a
Market Cap
182.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 205.58B | 68.50B | 49.97% |
| Dec 31, 2024 | 137.08B | 100.98B | 279.73% |
| Dec 31, 2019 | 36.10B | 15.56B | 75.75% |
| Dec 31, 2018 | 20.54B | 4.98B | 32.03% |
| Dec 31, 2017 | 15.56B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daewon Pharmaceutical | 605.43B |
| Jeil Pharmaceutical Co.,Ltd | 567.24B |
| Dongwha Pharm.Co.,Ltd | 496.39B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| JW Lifescience | 257.83B |
| Whan In Pharm | 255.21B |
| Samil Pharmaceutical Co.,Ltd | 210.25B |
| REYON Pharmaceutical | 145.93B |